Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

844
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
844
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

982
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
982
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

1.1K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

272
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
272

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural electrobiology: architecture of the bioelectric code.

Open biology·2026
Same author

Interactive Role of the DHPR β<sub>1a</sub> SH3 Domain in Skeletal Muscle Excitation-Contraction Coupling.

Biomolecules·2025
Same author

In situ exogenous alpha-synuclein aggregates inhibit murine ventricular voltage-gated inward sodium and outward potassium currents.

Journal of Parkinson's disease·2025
Same author

Veratridine-Induced Oscillations in Nav 1.7 but Not Nav 1.5 Sodium Channels Are Revealed by Membrane Potential Sensitive Dye.

Membranes·2025
Same author

Complex Actions of FKBP12 on RyR1 Ion Channel Activity Consistent with Negative Co-Operativity in FKBP12 Binding to the RyR1 Tetramer.

Cells·2025
Same author

Isoform-specific N-linked glycosylation of NaV channel α-subunits alters β-subunit binding sites.

The Journal of general physiology·2024

Related Experiment Video

Updated: Sep 7, 2025

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

2.7K

How does flecainide impact RyR2 channel function?

Samantha C Salvage1, Christopher L-H Huang1,2, James A Fraser2

  • 1Department of Biochemistry, University of Cambridge, Cambridge, UK.

The Journal of General Physiology
|June 17, 2022
PubMed
Summary
This summary is machine-generated.

Flecainide, an antiarrhythmic drug, acts on multiple sites of the cardiac ryanodine receptor (RyR2), not just the pore. This complex interaction influences calcium release and may explain its effectiveness in treating catecholaminergic polymorphic ventricular tachycardia (CPVT).

More Related Videos

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.3K
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.5K

Related Experiment Videos

Last Updated: Sep 7, 2025

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

2.7K
Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.3K
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.5K

Area of Science:

  • Cardiovascular Pharmacology
  • Molecular Cardiology
  • Ion Channel Physiology

Background:

  • Flecainide is a Class 1C antiarrhythmic agent targeting the NaV1.5 sodium channel.
  • It is clinically used for catecholaminergic polymorphic ventricular tachycardia (CPVT), often caused by RyR2 mutations.
  • The precise molecular mechanisms of flecainide's action on RyR2 and excitation-contraction coupling remain debated.

Purpose of the Study:

  • To investigate the direct molecular actions of flecainide on isolated cardiac ryanodine receptor (RyR2) channels.
  • To elucidate the binding sites and functional consequences of flecainide interaction with RyR2.
  • To understand how these interactions contribute to flecainide's antiarrhythmic effects in CPVT.

Main Methods:

  • Studies utilizing isolated RyR2 channels reconstituted into artificial lipid bilayers.
  • Characterization of flecainide binding kinetics and functional effects on channel activity.
  • Analysis of flecainide's impact on cation flux and sarcoplasmic reticulum (SR) Ca2+ release.

Main Results:

  • Flecainide exhibits multiple binding sites on RyR2, distinct from its NaV1.5 binding site.
  • These RyR2 binding sites include voltage-dependent pore interactions and voltage-independent peripheral sites.
  • Flecainide demonstrated at least four inhibitory and one activation site on RyR2, with complex effects on Ca2+ flux directionality.

Conclusions:

  • Flecainide's antiarrhythmic efficacy in CPVT likely involves complex, multi-site interactions with RyR2.
  • These actions extend beyond direct pore blockade, potentially involving modulation of counter-currents affecting SR membrane potential.
  • Further clarification of these molecular mechanisms could identify new drug targets for CPVT treatment.